Oxidative stress regulates left ventricular PDE5 expression in the failing heart - Wikidata - awgldk - TriplyDB

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

http://www.wikidata.org/entity/Q34105975

about

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension Therapeutic potential of PDE modulation in treating heart disease Phosphodiesterases and cardiac cGMP: evolving roles and controversies Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine The emperor's new clothes: PDE5 and the heart Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease.Endoplasmic reticulum stress sensor protein kinase R-like endoplasmic reticulum kinase (PERK) protects against pressure overload-induced heart failure and lung remodeling.Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy.Reduced cardiac fructose 2,6 bisphosphate increases hypertrophy and decreases glycolysis following aortic constriction Conserved expression and functions of PDE4 in rodent and human heart.Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling Knockdown of Akt1 promotes Akt2 upregulation and resistance to oxidative-stress-induced apoptosis through control of multiple signaling pathways The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases Exacerbated pulmonary arterial hypertension and right ventricular hypertrophy in animals with loss of function of extracellular superoxide dismutase.AMP activated protein kinase-α2 regulates expression of estrogen-related receptor-α, a metabolic transcription factor related to heart failure development.Differential expression of PDE5 in failing and nonfailing human myocardium Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells.Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations.Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications Best Practice BioBanking of Human Heart Tissue Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload.The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanism Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.Effect of asymmetric dimethylarginine (ADMA) on heart failure development.Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure.Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy.Loss of the eukaryotic initiation factor 2α kinase general control nonderepressible 2 protects mice from pressure overload-induced congestive heart failure without affecting ventricular hypertrophy.The NO/ONOO-cycle as the central cause of heart failure.Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure.Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension.Developments in heart failure 2010.

P2860

Q26741387-A39ECC66-B4A8-456C-9D9F-30C0F9651730 Q26750994-F7817D4D-32A8-4DAD-86EE-E732A2EE23E6 Q26852171-0216E074-B83D-4C8B-A5C9-2FEE410F4533 Q27005761-B3EFBE35-C277-4EA1-8C54-20560C245F2D Q27692588-C732F9EA-8FA8-498D-BB13-3F1378CC2063 Q27967859-188F7DF6-BA46-4D1B-A81B-87BD71C214EE Q28506246-5F9F775A-6D19-4B5B-B825-6F8E552EF73B Q28543897-297AA951-92FF-4B4C-98DB-C4521D9C343B Q33711368-5ED54CBE-187F-4833-8509-1E98F18A183D Q34173536-8623416A-8663-4381-AC5C-E73A4A4E4B9B Q34279254-7B91FD82-3F24-4FCA-B0BD-BAF90207DC3D Q34315276-7190E040-F420-4DDC-8F72-BC8AE72C1729 Q34545425-0E7AE109-40F6-40EF-9732-509CBCC4F1F7 Q34548139-0F788E6A-7AA5-449E-97A3-72BF25B3568F Q34634339-6B3CC6CF-F157-443D-B27A-0F0B36EB7E96 Q35031186-CDDB4E55-5773-4F27-A033-322DA3FFA9E6 Q35156618-D2054C0F-D644-4220-9D93-D85FC9007DAA Q35205619-C0175C94-812D-43DC-AA3D-9CE42BA50313 Q35238018-0763C3FA-BC59-4B30-866F-08C29EF2149E Q35680934-A024D2D1-43F7-4224-9976-2A101BCF7FFA Q36000073-820CDD57-4ECA-44ED-87D3-87E44EA1C79A Q36001831-5871BAF4-5E6A-4FA5-A25B-2FAA2D750930 Q36108598-49DE170B-5E37-4636-A329-73EDAF79A94E Q36128551-07BFFA0A-4611-4733-B773-2A12CC8FF4C7 Q36141348-3380125E-1081-474B-937A-92F8E8C00CF5 Q36191580-360D6669-357C-4AAD-B47C-3856DD72B4B5 Q36270020-21F970E1-CD47-485B-9729-D31E0F180E8C Q36460566-49AC23CB-37A7-45DC-84D0-C7FC621F69CF Q36688868-A734E427-19FF-42D9-AA01-54F25AB2CAE1 Q36908852-FC369B4E-55D1-45D4-962D-C99C797E571A Q37037569-A8BF0299-420A-4E72-A83F-0C05C0017441 Q37240478-78992940-78FC-4921-8029-64165E1F402A Q37245523-790B5B59-6B17-4AEE-8D61-D78F4E75C8FD Q37337837-DD538C9E-BB23-4B27-BF91-F27AEEAFF7CA Q37341337-1243FE98-2BFD-4775-AF3E-DC8EDE17D16A Q37365394-324C39C6-13E3-4830-BBFB-DF3B44DCCF18 Q37375441-690D4F69-3F7C-41D5-A066-AEB540E3C341 Q37678632-56BA31C1-ADEB-4464-AFD8-13280A3C261A Q37799652-99241D82-25D1-4001-85D7-AE8CEC43BB0F Q37859431-7839A6CE-0945-4E11-869E-85571C5F8E49

P2860

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

http://www.wikidata.org/entity/Q34105975

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@ast

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@en

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@nl

type

label

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@ast

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@en

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@nl

prefLabel

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@ast

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@en

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@nl

P1433

Q34105975-95AA1AE7-1379-4E2F-8EB4-DEDA29511B19

P1476

Q34105975-B3BA010B-C73A-4D86-A311-4AC8769BCC20

P2093

Q34105975-06F5944B-2B7D-4924-A38A-C82C58128F33

Q34105975-0AFAEEF4-E89F-4845-A680-78690BE3AEC3

Q34105975-24109FDB-4EBC-43E8-886C-5E2EE3EDEEEC

Q34105975-40AFE744-CFBE-4BEA-B95F-04F3A4DA7F48

Q34105975-640770F5-95A8-4409-8472-1FA27BB4CDEE

Q34105975-66CAB8DB-799B-4787-AB31-7E20DCC45C58

Q34105975-879A98B7-3A32-4DF0-BA58-C9C0F653A793

Q34105975-91505C0F-F770-4A47-BD28-B2EC02E1FF7A

Q34105975-9EDC438C-89A2-4A2B-8947-A7E50E0321BC

Q34105975-E60BDE79-CDB7-4031-B42B-FEB6544B0133

P2860

Q34105975-0CBAAAB2-8174-4BCD-908A-D301FAF03A00

Q34105975-0ED31498-8EEF-4C61-BA93-0C6B8885402D

Q34105975-136BA147-8B04-4C5C-85C4-4DB93E704073

Q34105975-265AAE07-5F7C-4F34-8AF4-5006CA7D717F

Q34105975-310AB5AA-31B5-413C-BEBA-D9B7F90404DB

Q34105975-4113898A-6249-491D-BE31-451AFC99ABA7

Q34105975-5B362909-3D0F-4A13-93CB-B5B27C912E83

Q34105975-62619C11-297B-488A-8C59-1008B49E3F48

Q34105975-648BFB84-15F0-48A8-8534-4428482440CC

Q34105975-758FB905-E559-412F-83DE-ACCB7BE43CBD

P304

Q34105975-A8C1F10F-6A7B-4079-B1DF-C0A4806342DF

P31

Q34105975-C1A8BC82-447C-4BD7-BB2C-CC3464D43194

P356

Q34105975-C89C84BA-6AB3-462C-B29A-C50B1BBFE0CF

P407

Q34105975-B95A46AC-85EC-462C-8062-25AB315B1F39

P433

Q34105975-B02B4923-FED8-438A-A879-CEE7808FF945

P478

Q34105975-022DBD2C-B008-4B44-898D-213F11582F49

P50

Q34105975-1629ED51-7400-4FF1-BB82-B7451D2B9FA4

Q34105975-2E5672F6-646B-419A-8CD2-965E195C7772

Q34105975-3C44069D-BFE9-4B64-8848-1309F87E917F

P577

Q34105975-C172553A-1291-46DD-A2CB-2D673E64AA8A

P698

Q34105975-E12B9F1C-3A60-44E6-BBD7-760EAD8B4E45

P932

Q34105975-3B8DFB1E-5CF9-43D9-8312-27B75C8D88EC

P356

CIRCULATIONAHA.109.906818

P1433

P1476

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

@en

P2093

Cris dos Remedios

http://www.w3.org/2001/XMLSchema#string

Daniel J Garry

http://www.w3.org/2001/XMLSchema#string

Guangshuo Zhu

http://www.w3.org/2001/XMLSchema#string

Jay H Traverse

http://www.w3.org/2001/XMLSchema#string

Jennifer L Hall

http://www.w3.org/2001/XMLSchema#string

Marc Pritzker

http://www.w3.org/2001/XMLSchema#string

Ping Zhang

http://www.w3.org/2001/XMLSchema#string

Sangjin Lee

http://www.w3.org/2001/XMLSchema#string

Xin Xu

http://www.w3.org/2001/XMLSchema#string

Xinli Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T

Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart.

Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle

Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load.

Disruption of sarcolemmal ATP-sensitive potassium channel activity impairs the cardiac response to systolic overload.

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association.

Nitroso-redox interactions in the cardiovascular system.

P304

1474-1483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.109.906818

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20308615

http://www.w3.org/2001/XMLSchema#string

P932

3110701

http://www.w3.org/2001/XMLSchema#string